Source: Cancer Therapy Advisor, June 2025
Neoadjuvant cobolimab and dostarlimab followed by surgery and adjuvant dostarlimab may confer benefits over perioperative pembrolizumab in patients with high-risk, resectable melanoma, according to research presented at the ASCO Annual Meeting 2025.
Researchers evaluated neoadjuvant cobolimab and dostarlimab as well as neoadjuvant dostarlimab alone, each followed by surgery and adjuvant dostarlimab, in the phase 2 NEO-MEL-T trial. The team did not compare these therapies to each other but compared them to a historical control treatment consisting of neoadjuvant and adjuvant pembrolizumab.